The saudi arabia diabetes drugs market size is expected to grow from USD 452.26 million in 2025 to USD 481.48 million in 2026 and is forecast to reach USD 658.43 million by 2031 at 6.46% CAGR over 2026-2031. This report is Segmented by Drug Class (Insulins, Oral Anti-Diabetics, Non-Insulin Injectable Drugs, and Combination Drugs), Drug Origin (Branded and Generic / Biosimilar) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).
Non-insulin injectables are forecast to post a 9.03% CAGR to 2031, the quickest among all classes. Local evidence shows oral semaglutide trimming HbA1c by 3.1% at 6 months and tirzepatide enabling 64.1% of patients to reach targets within 40 weeks. Combined with notable weight reductions, these outcomes drive rapid uptake in insured urban cohorts. Biosimilar makers are preparing GLP-1 filings to ride the wave once regulatory clarity improves.
Saudi Arabia Diabetes Drugs Market Trends and Insights
Growing prevalence of obesity & sedentary lifestyles
Obesity stabilized at 21.4% in 2023, yet 18.8% of obese Saudis already live with diabetes. Among people under 30, 14% now have the disease. Sugary beverages and fast food remain dietary staples, especially in cities, while adherence to the Ministry of Health guideline of 150 minutes of weekly exercise is weak. Demand therefore leans toward agents that address glycemic control and weight, positioning GLP-1 products as first-line injectable choices. The government spends USD 26 billion yearly on diabetes care, making prevention a parallel priority.Rising reimbursement for innovative antidiabetics
The Council of Health Insurance’s Saudi Billing System has standardized codes and improved transparency, smoothing the path for premium therapies. Private-insurance uptake should widen by 2030, expanding access for urban professionals. Managed-entry agreements balance cost and value, allowing companies to collect real-world evidence while patients gain earlier access. Oral semaglutide cut HbA1c by 3.1% at 6 months in local studies, proof that outcomes-based payments can work. Pharmaceutical firms now invest more heavily in post-market surveillance, encouraged by these reimbursement shifts.High cost of GLP-1s & novel dual agonists
Premium pricing limits access even though GLP-1s lower complications over time. A global shortage has heightened prices; biosimilar competition is sparse because manufacturing is complex. Tirzepatide hits HbA1c goals for nearly two-thirds of local users, yet the out-of-pocket burden still deters uptake. Generic liraglutide by Hikma could narrow the gap, but material price relief remains gradual. Insurers test managed-entry models to widen coverage but progress varies across schemes.Other drivers and restraints analyzed in the detailed report include:
- National Transformation Program focus on chronic diseases
- Expansion of private-sector specialty diabetes centers
- Stringent SFDA pharmacovigilance delaying biosimilar launches
Segment Analysis
Insulins captured 50.62% of Saudi Arabia diabetes drugs market share in 2025. Stable treatment algorithms, broad physician familiarity and reimbursement support keep demand strong. Saudi Arabia diabetes drugs market size for insulins is projected to climb steadily though at a slower pace than innovative injectables. Once-weekly insulin icodec promises higher adherence, and localization efforts by NUPCO, Novo Nordisk and Sanofi strengthen supply security.Non-insulin injectables are forecast to post a 9.03% CAGR to 2031, the quickest among all classes. Local evidence shows oral semaglutide trimming HbA1c by 3.1% at 6 months and tirzepatide enabling 64.1% of patients to reach targets within 40 weeks. Combined with notable weight reductions, these outcomes drive rapid uptake in insured urban cohorts. Biosimilar makers are preparing GLP-1 filings to ride the wave once regulatory clarity improves.
Complete Report Scope:
- By Drug Class
- Insulins
- Oral Anti-diabetic Drugs
- Non-Insulin Injectable Drugs
- Combination Drugs
- By Drug Origin
- Branded Drugs
- Biosimilar / Generic Drugs
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
List of Companies Covered in this Report:
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Merck
- AstraZeneca
- Boehringer Ingelheim
- Janssen
- Takeda Pharmaceuticals
- Pfizer
- Novartis
- Astellas Pharma
- Gulf Pharmaceutical Industries (Julphar)
- Glenmark Pharmaceuticals
- Biocon
- Hikma Pharmaceuticals
- Viatris
- Riyadh Pharma
- Tabuk Pharmaceuticals
- Spimaco
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size and Growth Forecasts (Value-USD)
6 Competitive Landscape
7 Market Opportunities and Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk A/S
- Sanofi
- Eli Lilly and Company
- Merck & Co.
- AstraZeneca
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Takeda Pharmaceutical Company
- Pfizer
- Novartis
- Astellas Pharma
- Gulf Pharmaceutical Industries (Julphar)
- Glenmark Pharmaceuticals
- Biocon Limited
- Hikma Pharmaceuticals
- Viatris
- Riyadh Pharma
- Tabuk Pharmaceuticals
- Spimaco
